Anti-BAFF/BLyS Antibody, Rabbit Polyclonal

1/2
Price:
Size:
Number:

Anti-BAFF/BLyS Antibody, Rabbit Polyclonal General Information

Product name
Anti-BAFF/BLyS Antibody, Rabbit Polyclonal
Validated applications
WB,ELISA,IP
Species reactivity
Reacts with: Human
Specificity
Human BAFF/BLyS
Immunogen
Recombinant Human BAFF / TNFSF13B protein (Catalog#10056-HNAE)
Preparation
Produced in rabbits immunized with purified, recombinant Human BAFF / TNFSF13B (rh BAFF / TNFSF13B; Catalog#10056-HNAE; Q9Y275-1; Ala134-Leu285). BAFF / TNFSF13B specific IgG was purified by Human BAFF / TNFSF13B affinity chromatography.
Source
Polyclonal Rabbit IgG
Purification
Protein A & Antigen Affinity
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

Anti-BAFF/BLyS Antibody, Rabbit Polyclonal Validated Applications

Application Dilution
WB 1:500-1:2000
ELISA 1:5000-1:10000
IP 1-4 μL/mg of lysate
Please Note: Optimal concentrations/dilutions should be determined by the end user.

Anti-BAFF/BLyS Antibody, Rabbit Polyclonal Images

BAFF was immunoprecipitated using:

Lane A:0.5 mg Jurkat Whole Cell Lysate

Lane B:0.5 mg HL-60 Whole Cell Lysate

2 µL anti-BAFF rabbit polyclonal antibody and 15 μl of 50 % Protein G agarose.

Primary antibody:

Anti-BAFF rabbit polyclonal antibody,at 1:200 dilution

Secondary antibody:

Dylight 800-labeled antibody to rabbit IgG (H+L), at 1:5000 dilution

Developed using the odssey technique.

Performed under reducing conditions.

Predicted band size: 31 kDa

Observed band size: 31 kDa

Anti-BAFF rabbit polyclonal antibody at 1:500 dilution

Lane A: Jurkat Whole Cell Lysate

Lysates/proteins at 30 μg per lane.

Secondary

Goat Anti-Rabbit IgG H&L (Dylight800) at 1/10000 dilution.

Developed using the Odyssey technique.

Performed under reducing conditions.

Predicted band size:31 kDa

Observed band size:36 kDa

(We are unsure as to the identity of these extra bands.)

Anti-BAFF/BLyS Antibody, Rabbit Polyclonal: Synonyms

Anti-BAFF Antibody; Anti-BLYS Antibody; Anti-CD257 Antibody; Anti-DTL Antibody; Anti-TALL-1 Antibody; Anti-TALL1 Antibody; Anti-THANK Antibody; Anti-TNFSF20 Antibody; Anti-ZTNF4 Antibody

BAFF/BLyS Background Information

B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is a single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors are a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS is an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.
Full Name
tumor necrosis factor (ligand) superfamily, member 13b
References
  • Nardelli B, et al. (2002) B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma. 43(7): 1367-73.
  • Stohl W. (2006) Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 6(4): 51-8.
  • Cancro MP, et al. (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 119(5): 1066-73.

Standard Antibody Development Service

Rabbit MAb

Mouse MAb

Rabbit PAb

Fast Antibody Development Service

Mouse MAb

Rabbit PAb

Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.